1. Inicio
  2. Publicaciones
  3. Spanish Society of Hospital Pharmacy Position Statement on Telepharmacy: Recommendations for its implementation and development

Spanish Society of Hospital Pharmacy Position Statement on Telepharmacy: Recommendations for its implementation and development

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Morillo-Verdugo, R
  • Margusino-Framinan, L
  • Morell-Baladron, A
  • Barreda-Hernandez, D
  • Rey-Pineiro, XM
  • Negro-Vega, E
  • Delgado-Sanchez, O

Grupos

Abstract

The use of information and communication technologies have nowadays become part and parcel of hospital pharmacy practice. Against this background, it is hardly surprising that Telepharmacy has sparked the interest of a large number of stakeholders. In this respect, the Spanish Society of Hospital Pharmacy has developed a definition of the concept and outlined the conditions under which Telepharmacy should operate. It has also shared its institutional stance on the subject through a position statement that states that Telepharmacy is the provision of pharmaceutical care at a distance through information and communication technologies. Telepharmacy practice includes activities such as therapeutic validation, drafting of clinical documents, provision of pharmaceutical care, therapeutic follow-up, adherence monitoring, drug education and information, coordination between healthcare providers and evaluation of health outcomes. The clinical tasks performed as part of Telepharmacy practice must adhere to a standardized procedure and revolve around the patient's clinical record. Access to Telepharmacy must be provided without discrimination. The service comprises four main activities: pharmacotherapeutic follow-up; patient and caregiver-directed education and information-dissemination; coordination with healthcare providers from the same or different hospitals; and remote informed home drug delivery. Implementation of Telepharmacy requires an adjustment of human (training and capacity-building) and technological resources (validation, interoperability, confidentiality). It must also comply with the laws and regulations in force both at a regional and a national level. Telepharmacy procedures must also be adapted to the relevant ethical standards and codes of good practice. Appropriate indicators must be used to evaluate the performance of Telepharmacy and its impact on health outcomes. According to Spanish Society of Hospital Pharmacy Telepharmacy is a necessary complementary tool to provide specialized pharmaceutical care and thereby improve health outcomes and maximize patient safety and satisfaction.

Datos de la publicación

ISSN/ISSNe:
1130-6343, 0214-753X

FARMACIA HOSPITALARIA  EDITORIAL GARSI

Tipo:
Article
Páginas:
174-181
Factor de Impacto:
0,264 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 22

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Telepharmacy; Telemedicine; Pharmaceutical care; Hospital pharmacy service; Health information technologies; Clinical pharmacist; Patient-centered care; Access to healthcare

Proyectos asociados

PREVALENCIA, FACTORES ASOCIADOS Y COMPLEJIDAD FARMACOTERAPEUTICA DE LA POLIFARMACIA EN PACIENTES VIH+ EN ESPAÑA. ESTUDIO POINT.

Investigador Principal: EMILIO MONTE BOQUET

RMV-FAR-2015-01 . 2017

EVALUACIÓN DE LA USABILIDAD DE UNA APLICACIÓN MÓVIL EN PACIENTES DIAGNOSTICADOS DE MIELOMA MÚLTIPLE.

Investigador Principal: EMILIO MONTE BOQUET

SEFH-APP-MM . 2017

FACTORES PRONÓSTICO EN EL HEMANGIOMA INFANTIL.

Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS

HUF-HMG-2017-01

ESTUDIO DE EVALUACIÓN EN UN ENTORNO REAL DEL USO DE AZTREONAM LISINA INHALADA EN PACIENTES CON FIBROSIS QUÍSTICA: REAZLI-FQ.

Investigador Principal: EMILIO MONTE BOQUET

AFP-AZT-2017-01 . 2018

EVALUACION DE LA CALIDAD DE VIDA RELACIONADA CON LA SALUD DURANTE EL TRATAMIENTO COMBINADO DE LA HEPATITIS CRONICA POR EL VIRUS DE LA HEPATITIS C EN CONDICIONES DE PRACTICA CLINICA HABITUAL.

Investigador Principal: EMILIO MONTE BOQUET

SCH-PEG-2007-02 . 2009

INTERVENCIÓN FARMACÉUTICA PARA LA MEJORA DEL RIESGO CARDIOVASCULAR EN PACIENTES VIH EN TRATAMIENTO ANTIRRETROVIRAL ACTIVO. ESTUDIO INFAMERICA.

Investigador Principal: EMILIO MONTE BOQUET

SEF-VIH-2012-01

ESTUDIO SOBRE CUMPLIMIENTO TERAPÉUTICO EN PACIENTES CON ARTRITIS REUMATOIDE EN TRATAMIENTO CON FÁRMACOS BIOLÓGICOS DE ADMINISTRACIÓN SUBCUTÁNEA. ESTUDIO “ARCO”.

Investigador Principal: JOSÉ ANDRÉS ROMÁN IVORRA

MSD-ART-2013-01 . 2014

RIBAVIRINA ORAL PARA EL TRATAMIENTO DE INFECCIONES POR VIRUS RESPIRATORIO SINCITIAL EN PACIENTES TRASPLANTADOS DE PULMÓN.

Investigador Principal: MARÍA JESÚS CUELLAR MONREAL

MCM-RIB-2015-01

Cita

Compartir